Cagrilintide

ID: cagrilintide

Aliases: Cagri, amylin analog, CAGRILINTIDE

Type: compound

Route/form: subcutaneous injection in trials

Status: investigational

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, non-human/mechanistic, review/regulatory

Source types: early_human, human_rct, mechanistic, meta_analysis, review

Linked sources: 10

Broad outcomes: Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• amylin receptor agonist

Optimization domains

• metabolic
• obesity

Research basis

• Standalone cagrilintide has human obesity dose-finding data through long-acting amylin biology, and development papers explain why the molecule was engineered to avoid native amylin instability.
• CagriSema phase 2/3 data and meta-analysis evidence show why the amylin pathway is being paired with GLP-1 therapy for larger weight-loss effects.
• Blood-pressure and type 2 diabetes trial data add cardiometabolic context beyond appetite suppression alone.

Limits, risks, and missing evidence

• Standalone cagrilintide evidence and cagrilintide-plus-semaglutide evidence should not be collapsed into the same claim.
• GI tolerability overlaps with incretin agents, and combination use complicates attribution.
• The evidence is strong for weight management development, not for direct performance, anabolic, or stimulant-like effects.

Risk flags

• investigational
• metabolic endocrine
• medical supervision

Linked papers, labels, and reviews

1. Once-weekly cagrilintide for weight management in people with overweight and obesity
   human_rct / pubmed_cagrilintide_phase2_2021
   Dose-finding phase 2 trial.
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide 2.4 mg
   early_human / pubmed_cagrilintide_semaglutide_phase1b
   Randomized phase 1b coadministration study; early human bridge for cagrilintide plus semaglutide before later phase 2/3 trials.
3. Co-administered once-weekly cagrilintide with semaglutide in type 2 diabetes
   human_rct / pubmed_cagrisema_t2d_phase2_2023
   Phase 2 active-controlled trial; useful bridge between early coadministration physiology and phase 3 obesity results.
4. Coadministered cagrilintide and semaglutide in adults with overweight or obesity
   human_rct / pubmed_cagrisema_redefine1_2025
   REDEFINE 1 phase 3 obesity trial for cagrilintide plus semaglutide; combo evidence should be kept separate from standalone cagrilintide claims.
5. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
   human_rct / pubmed_cagrisema_redefine2_2025
   REDEFINE 2 phase 3 trial in obesity/overweight with type 2 diabetes.
6. Blood pressure changes with cagrilintide plus semaglutide treatment
   human_rct / pubmed_cagrisema_blood_pressure_2025
   CagriSema human cardiometabolic endpoint analysis from obesity trial data.
7. Efficacy and safety of cagrilintide plus semaglutide for overweight and obesity: systematic review and meta-analysis
   meta_analysis / pubmed_cagrisema_meta_2026
   Human evidence synthesis for CagriSema; useful for keeping combo claims separate from standalone semaglutide.
8. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
   meta_analysis / pubmed_cagrilintide_cagrisema_meta_2024
   Meta-analysis covering cagrilintide alone and CagriSema; useful synthesis but limited by few RCTs and combination attribution issues.
9. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
   review / pubmed_cagrilintide_obesity_review_2023
   Mechanistic review of cagrilintide as a long-acting amylin analog, including amylin satiety biology and pairing with semaglutide.
10. Development of Cagrilintide, a Long-Acting Amylin Analogue
    mechanistic / pubmed_cagrilintide_development_2021
    Drug-development paper covering structure/activity work that produced lipidated long-acting cagrilintide for obesity trials.